60 Degrees Pharmaceuticals Inc (SXTP) - News Archive

In a strategic maneuver to secure its standing on the Nasdaq exchange, 60 Degrees Pharmaceuticals (SXTP) has announced a 1-for-5 reverse stock split, scheduled to take effect on February 24, 2025. This measure will allo...

In a decisive move reflecting both resilience and forward-thinking strategy in a challenging market, 60 Degrees Pharmaceuticals has successfully closed a registered direct offering totaling $1.075 million. This signific...

60 Degrees Pharma Completes $1.043 Million Registered Direct Offering: A Strategic Move to Enhance Operational FlexibilityIn a significant development for the biotechnology sector, 60 Degrees Pharma (Nasdaq: SXTP) recen...

In a strategic move to bolster its financial foundation and support its corporate initiatives, 60 Degrees Pharmaceuticals Inc. (Nasdaq: SXTP) recently announced the culmination of a $1.043 million registered direct offe...

In a groundbreaking initiative set to enhance the treatment landscape for persistent babesiosis, 60 Degrees Pharmaceuticals has announced the enrollment of its first patient in a clinical study evaluating tafenoquine. T...

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis: A Major Step Forward at Brigham and Women s Hospital60 Degrees Pharmaceuticals, a leader in the development of innovative therapies for infec...

In a groundbreaking move to address the pressing health concerns posed by babesiosis, Sixty Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) has entered a strategic patent license agreement with Tufts Medical Center. This pa...

In a significant development for global health and pharmaceutical marketing, 60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) has announced a promotional pilot program aimed at increasing awareness around ARAKODA, its inn...

Overview of the Private PlacementnnIn a significant development for both its working capital and research and development initiatives, 60 Degrees Pharmaceuticals, Inc. has successfully closed a private placement totalin...

60 Degrees Pharmaceuticals Raises $4M through Private Placement, Regains Nasdaq Compliance, and Announces Reverse Stock Split60 Degrees Pharmaceuticals, a biotechnology company focused on developing treatments for infec...

Over the past few years, 60 Degrees Pharmaceuticals has undergone a series of ups and downs, with the recent achievement of Nasdaq compliance serving as a remarkable milestone in its journey. The Nasdaq stock market req...

In the ever-evolving pharmaceutical sector, strategic collaborations are pivotal for advancing clinical research and development. Recently, 60 Degrees Pharmaceuticals Inc. announced an important partnership with the Uni...

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock SplitOn August 12, 2024, 60 Degrees Pharmaceuticals (NASDAQ: SXTP) made a significant announcement regarding its stock. The pharmaceutical company disclosed...

In a groundbreaking development for the pharmaceutical and military cooperation sectors, 60 Degrees Pharmaceuticals has proudly announced its recent award of a significant contract with the U.S. Army. This collaboration...

:60 Degrees Pharmaceuticals (60P) has recently announced the signing of clinical trial agreements with renowned research institutions, including Yale University, Tufts University, and Rhode Island Hospital. This strateg...

Tafenoquine as a Novel Therapy for Persistent Babesiosis in Immunocompromised Patients: A Pioneering Clinical Trial by 60 Degrees Pharmaceuticals Babesiosis, a tick-borne parasitic infection caused primarily by Babesia...

In an exciting move towards combating the tick-borne disease babesiosis, 60 Degrees Pharmaceuticals (60P) will commence the first-ever clinical trial of tafenoquine at Tufts Medical Center. With enrollment set to begin...

Exploring the Link Between Babesia Infections and Chronic Fatigue Syndrome: A New Study Funded by 60 Degrees PharmaceuticalsChronic Fatigue Syndrome (CFS), also known as myalgic encephalomyelitis (ME), remains one of th...

Innovative Drug, Tafenoquine, Pioneers New Frontiers in Infectious Disease ResearchIn a groundbreaking move, 60 Degrees Pharmaceuticals (60 Degrees Pharma) has set in motion a comprehensive clinical trial of Tafenoquine...

FDA Provides Positive Feedback on Tafenoquine-Babesiosis Clinical Trial Protocol; Promising Research Partnership Announced In a significant development for the biotechnology industry, 60 Degrees Pharmaceuticals (60P) ha...